Pharmaceuticals News and Research

RSS

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Cipher Pharmaceuticals Inc. today announced that it has reached the enrollment mid-point in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. To date, more than 400 patients have been enrolled. Achieving this milestone triggers a US$2.0 million milestone payment from Ranbaxy Pharmaceuticals Inc., Cipher's U.S. marketing and distribution partner.

1 Apr 2010

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months and fiscal year ended December 31, 2009.

1 Apr 2010

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities Commission for a best efforts offering to sell up to $40.0 million of units consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock. The offering anticipates including shares of common stock to be sold by selling stockholders.

1 Apr 2010

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, today announced its 2009 year-end financial results.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

Investment report on ADVENTRX Pharmaceuticals

BeaconEquity.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

1 Apr 2010

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Health care law: Planned, well-financed lobbying strategy leads to impressive list of wins for U.S. drug industry

Emerging Healthcare Solutions, Inc.. The U.S. drug industry fended off price curbs and other hefty restrictions in The President's health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage. Lobbyists beat back proposals to allow importation of low-cost medicines and to have Medicare negotiate drug prices with companies.

1 Apr 2010

Pfizer admits paying $35 million to doctors over last 6 months

Pfizer among other large pharmaceutical companies recently disclosed payments to doctors and other medical professionals for consulting and speaking on its behalf and also some sponsorship of clinical trials. On Wednesday in an announcement the company spokesperson revealed that they had paid a whopping $20 million to 4,500 doctors and other medical professionals in the last six months of 2009. Pfizer also accepted that they paid $15.3 million to 250 academic medical centers and other research groups for clinical trials in the same period. This disclosure is only about payments made within the US.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Teva Pharmaceutical Industries Ltd. announced today that patent infringement litigation pertaining to Teva's generic version of sanofi-aventis and Debiopharm's Eloxatin (oxaliplatin injection) has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties.

1 Apr 2010

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications.

1 Apr 2010

Conventional analgesics to drive acute pain market over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

1 Apr 2010

Symyx Technologies forms alliance with Pistoia Alliance

Symyx Technologies, Inc. today announced it has joined the Pistoia Alliance, a non-profit group that promotes collaboration to streamline non-competitive elements of pharmaceutical and life science discovery workflows. The alliance was initially formed by major global pharmaceutical companies including Pfizer, GlaxoSmithKline, Novartis, and AstraZeneca.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

New health care reform law includes patient safety provisions

While most of the attention surrounding the landmark health care reform measure just signed into law has focused on how it expands access to affordable insurance coverage, it also enacts important initiatives that will improve patient safety, according to Consumers Union, the nonprofit publisher of Consumer Reports.

1 Apr 2010

Pharmaceuticals News and Research

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Soligenix's revenues for 2009 increase by 22%

Investment report on ADVENTRX Pharmaceuticals

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

BeaconEquity.com announces investment report featuring OXiGENE

Health care law: Planned, well-financed lobbying strategy leads to impressive list of wins for U.S. drug industry

Pfizer admits paying $35 million to doctors over last 6 months

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

Conventional analgesics to drive acute pain market over the next decade

Symyx Technologies forms alliance with Pistoia Alliance

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

New health care reform law includes patient safety provisions

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence